Veradermics, Incorporated MANE
$135.29
-13.59%
at last close
Analyst Consensus
- Consensus Rating
- Buy (7 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $169.67
- Implied Upside
- +25.4%
- Price Target Range
- $135.00 – $204.00
- Analysts (12 mo)
- 7
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-11-10 | CitigroupGeoff Meacham |
Maintains | Buy | $160 → $175 |
| 2026-11-09 | Leerink PartnersMarc Goodman |
Maintains | Outperform | $135 → $150 |
| 2026-10-22 | B. Riley SecuritiesMayank Mamtani |
Maintains | Buy | $170 → $204 |
| 2026-10-19 | Cantor FitzgeraldPrakhar Agrawal |
Reiterates | Overweight | — |
| 2026-10-19 | NeedhamSerge Belanger |
Maintains | Buy | $164 → $172 |
| 2026-07-16 | CitigroupGeoff Meacham |
Maintains | Buy | $135 → $160 |
| 2026-07-15 | NeedhamSerge Belanger |
Maintains | Buy | $136 → $164 |
| 2026-07-15 | B. Riley SecuritiesMayank Mamtani |
Initiates coverage on | Buy | $170 |
| 2026-07-07 | JefferiesRoger Song |
Maintains | Buy | $138 → $182 |
| 2026-06-16 | LifeSci CapitalRami Katkhuda |
Initiates coverage on | Outperform | $135 |
| 2026-06-02 | NeedhamSerge Belanger |
Initiates coverage on | Buy | $136 |
| 2026-05-18 | CitigroupGeoff Meacham |
Maintains | Buy | $120 → $135 |
| 2026-04-22 | Leerink PartnersMarc Goodman |
Maintains | Outperform | $75 → $90 |
| 2026-03-02 | Cantor FitzgeraldPrakhar Agrawal |
Initiates coverage on | Overweight | — |
| 2026-03-02 | CitigroupGeoff Meacham |
Initiates coverage on | Buy | $85 |
| 2026-03-02 | Leerink PartnersMarc Goodman |
Initiates coverage on | Outperform | $75 |
| 2026-03-02 | JefferiesRoger Song |
Initiates coverage on | Buy | $75 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $135.29
- Market Cap
- $6.61 billion
- 52-Week Range
- $32.00 – $156.63
- Average Volume
- 822K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.